A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study.
Ting Deng, Kaijiang Liu, Liang Chen...
https://pubmed.ncbi.nlm.nih.gov/37116952/Actively Recruiting
Led by Sun Yat-sen University · Updated on 2021-01-15
656
Participants Needed
1
Research Sites
156 weeks
Total Duration
Researchers are evaluating the effects of comprehensive staging surgery with and without lymphadenectomy in women with early-stage epithelial ovarian cancer, specifically FIGO stage IA to IIA. This randomized phase III study aims to compare the safety and effectiveness of these two surgical approaches on survival and quality of life. The study is designed to better understand whether omitting lymphadenectomy impacts patient outcomes, including progression-free survival and overall survival. Participants will be assigned to one of two surgical groups either comprehensive staging surgery without lymphadenectomy or completion staging surgery including systematic pelvic and para-aortic lymphadenectomy. Both approaches involve open or minimally invasive surgery, cytologic examinations, removal of the ovaries and uterus, and omentectomy. The lymphadenectomy group will have extensive removal of lymph nodes in pelvic and para-aortic areas, while the no lymphadenectomy group will have visual inspection and biopsy of suspicious lymph nodes only. Adjuvant chemotherapy will be given following national guidelines. During the study, participants will be followed every three months for the first two years, then every six months thereafter. Researchers will assess progression-free survival, overall survival, quality of life at baseline, six months, and one year post-surgery, postoperative complications, and lymph node recurrence rates over three years. The total study duration allows monitoring of long-term outcomes up to 100 months. Participants will undergo regular evaluations to track their health and recovery throughout the trial.
CONDITIONS
Lymphadenectomy in Early Ovarian Cancer
J
Jihong Liu, Ph.D.
T
Ting Deng, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sun Yat-sen University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery
Participants undergo comprehensive staging surgery with or without systematic pelvic and para-aortic lymphadenectomy depending on their randomized group.
1 surgical visit (in-person)
Duration - Up to 3 years
Participants attend follow-up visits to monitor recovery, assess for complications, and receive adjuvant chemotherapy as recommended by clinical guidelines.
Every 3 months for the first 2 years, then every 6 months thereafter
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ting Deng, Kaijiang Liu, Liang Chen...
https://pubmed.ncbi.nlm.nih.gov/37116952/Sun Yat-sen University
Lead Sponsor